A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
← catalyst calendarNCT03314181 · readout ≤ 1,746 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →. With Janssen Research & Development, LLC.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
156actual
Sites
40
Countries
Australia, Canada, Denmark +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-04-02 | actual | When the study began enrolling |
| Primary completion | May 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2017-10-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Multiple Myeloma
Interventions
- Drug: Dexamethasone
- Drug: Daratumumab
- Drug: Venetoclax — also filed as ABT-199, Venclexta
- Drug: Bortezomib
Primary outcomes
what the primary-completion date above is the date OFOverall Response Rate (ORR)
measured Up to approximately 3.5 years after the last participant is enrolled
Very Good Partial Response or Better Response Rate (VGPR)
measured Up to approximately 3.5 years after the last participant is enrolled
Complete Response (CR) or Better Rate
measured Up to approximately 3.5 years after the last participant is enrolled
Time to Response (TTR)
measured Up to approximately 3.5 years after the last participant is enrolled
Duration of Response (DOR)
measured Up to approximately 3.5 years after the last participant is enrolled
Time to Progression (TTP)
measured Up to approximately 3.5 years after the last participant is enrolled
Progression-Free Survival (PFS)
measured Up to approximately 3.5 years after the last participant is enrolled
Overall Survival (OS)
measured Up to approximately 3.5 years after the last participant is enrolled
Publications
- PMID 34388020 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed